507 related articles for article (PubMed ID: 20730695)
1. The use of vasopressin receptor antagonists in hyponatremia.
Khanna A; Menon MC
Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for hyponatremia in heart failure.
Goldsmith SR
Congest Heart Fail; 2010 Jul; 16 Suppl 1():S15-8. PubMed ID: 20653706
[TBL] [Abstract][Full Text] [Related]
4. Vasopressin-receptor antagonists.
Hoorn EJ; Zietse R
Future Cardiol; 2010 Jul; 6(4):523-34. PubMed ID: 20608824
[TBL] [Abstract][Full Text] [Related]
5. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Palm C; Pistrosch F; Herbrig K; Gross P
Am J Med; 2006 Jul; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
[TBL] [Abstract][Full Text] [Related]
6. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Wong F; Blei AT; Blendis LM; Thuluvath PJ
Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
[TBL] [Abstract][Full Text] [Related]
7. Vasopressin dysregulation and hyponatremia in hospitalized patients.
Multz AS
J Intensive Care Med; 2007; 22(4):216-23. PubMed ID: 17712057
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Ferguson JW; Therapondos G; Newby DE; Hayes PC
Clin Sci (Lond); 2003 Jul; 105(1):1-8. PubMed ID: 12639215
[TBL] [Abstract][Full Text] [Related]
9. [Aquaretic drugs--a new therapeutic principle in treatment of hyponatremia?].
Hensen J; Buchfelder M; Gross P
Fortschr Med; 1997 Jun; 115(17):46-50. PubMed ID: 9312543
[TBL] [Abstract][Full Text] [Related]
10. Vasopressin antagonists: role in the management of hyponatremia.
Yeates KE; Morton AR
Am J Nephrol; 2006; 26(4):348-55. PubMed ID: 16837788
[TBL] [Abstract][Full Text] [Related]
11. [Vasopressin antagonists in treatment of hyponatremia].
Olszewski W; Głuszek J
Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
[TBL] [Abstract][Full Text] [Related]
12. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
Patel GP; Balk RA
Clin Ther; 2007 Feb; 29(2):211-29. PubMed ID: 17472815
[TBL] [Abstract][Full Text] [Related]
13. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
Decaux G
J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
[TBL] [Abstract][Full Text] [Related]
14. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
[TBL] [Abstract][Full Text] [Related]
15. Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism.
Rosner MH; Ronco C
Congest Heart Fail; 2010 Jul; 16 Suppl 1():S7-14. PubMed ID: 20653716
[TBL] [Abstract][Full Text] [Related]
16. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
17. [Vasopressin receptor antagonists: the vaptans].
Villabona C
Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
[TBL] [Abstract][Full Text] [Related]
18. Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists.
Elhassan EA; Schrier RW
Curr Opin Nephrol Hypertens; 2011 Mar; 20(2):161-8. PubMed ID: 21252664
[TBL] [Abstract][Full Text] [Related]
19. [Disorders of body water regulation and the therapy--vasopressin antagonists].
Ishikawa S; Saito T
Nihon Naika Gakkai Zasshi; 1997 Sep; 86(9):1654-9. PubMed ID: 9410978
[No Abstract] [Full Text] [Related]
20. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
Gargani L; Schmidt PH; Gheorghiade M
Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1505-13. PubMed ID: 22103869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
